This is the authors' abstract. We don't add key points for this paper.
Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival and objective response rate by cohort. b, Overall survival by cohort.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Maron et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: